A century of Central Coast health
Despite vaccines, a drop in infectious rates and cities shifting from protective health measures to preventative approaches, 2021 resumes the two-year trend of health care as a focal issue in the U.S., as cities direct what they hope to be the COVID’s third and final act. With hospitals and clinics already in their communities’ spotlight, Read More →
FDA gives Amgen priority review for asthma treatment
Thousand Oaks-based Amgen received a priority review for tezepelumab, a treatment for asthma, from the U.S. Food and Drug Administration, the biotech giant announced July 7. According to Amgen, tezepelumab is the first and only biologic to consistently and significantly reduce asthma exacerbations in a broad population of clients in phase 2 and 3 trials. Read More →
Cities, counties wind down COVID enforcement cases
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Doctor from SLO County will join Team USA in Tokyo
A Central Coast doctor will be on hand to assist athletes when the Olympic games start in Tokyo. Dignity Health orthopedic surgeon Dr. Jonathon Fow is heading to Japan later this month as a Team USA physician at the Tokyo 2021 Olympic Games, which begin July 23. Fow is a sports medicine orthopedic surgeon, and Read More →
Camarillo hospital puts ‘Camarillo’ in its name
St. John’s Pleasant Valley Hospital has changed its name to St. John’s Hospital Camarillo, the hospital’s nonprofit parent, Dignity Health, announced July 6. Dignity said the hospital is changing its name to “better identify the hospital with the community it serves.” Hospital leaders don’t expect the name change to impact hospital operations or patient care. Read More →
Arcutis ends phase 2 trials on potential skin treatment
Shares of Westlake Village-based Arcutis Biotherapeutics dropped by as much as 5% during the trading day July 1, after the biotech company terminated phase 2 trials for a potential treatment. Arcutis, a biotech company focused on creating dermatology treatments, has announced July that it had terminated phase 2a and 2b trials for evaluating ARQ-252, a Read More →
UCLA Health continues northward march
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
